What HebeCell does

HebeCell is a privately held, pre-clinical biotechnology company founded in 2016 and based in Natick, Massachusetts, that develops off-the-shelf allogeneic natural killer (NK) cell therapies for cancer immunotherapy and other diseases. The company's core offering is a proprietary 3D-iPSC (three-dimensional induced pluripotent stem cell) platform that enables scalable, consistent production of NK cells from iPSCs, addressing the manufacturing and accessibility limitations inherent to patient-specific autologous cell therapies. The platform is positioned to serve cancer patients requiring immunotherapy, including those with hematological malignancies and solid tumors, with potential applicability to other disease areas.

The company's business model is currently non-commercial: as a development-stage biotech, HebeCell generates no product revenue and has no publicly disclosed pricing structure. Its go-to-market posture is defined by R&D progression and strategic partnering rather than direct sales. In August 2021, Jacobio Pharmaceuticals made a $53 million strategic investment and entered a co-development partnership to advance the 3D-iPSC NK cell pipeline, with the deal including leadership changes. This followed an earlier $10 million round led by Aceso Biotech Venture Fund in April 2020, bringing cumulative disclosed funding to approximately $63 million.

HebeCell operates in a competitive landscape alongside roughly a dozen other developers pursuing iPSC-derived NK cell therapies, including named peers such as Century Therapeutics and Fate Therapeutics. The company employs between 11 and 50 people, led by founder and Chief Scientific Officer Allen Feng, President and CEO John Lu, VP of Finance and Administration Lily Tang, and VP of Regulatory Affairs and Quality Assurance Edmund Mickunas. No clinical trial initiations, IND filings, regulatory designations, or product approvals are disclosed in available sources, placing HebeCell firmly in the preclinical development phase with commercialization dependent on successful platform translation into clinical-stage assets.

Name

HebeCell

Legal name

Hebecell

Website

https://hebecellcorp.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

HebeCell is a pre-clinical biotechnology company developing off-the-shelf allogeneic natural killer (NK) cell therapies using a proprietary 3D-iPSC platform for cancer immunotherapy and other diseases, headquartered in Natick, Massachusetts.

Ownership category

akta.pro rank

Product category

Cell Therapy / Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Natural killer cell therapy
• IPSC-derived cell therapy
• Cancer immunotherapy
• Allogeneic cell therapy
• Cell-based therapeutics

Headquarters

HQ city

Natick

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Marketing channels2 records

Core offering

HebeCell develops and commercializes cell-based therapeutics using its proprietary 3D-iPSC platform to manufacture off-the-shelf allogeneic natural killer (NK) cell therapies. The company's products target cancer immunotherapy indications, including hematological malignancies and solid tumors, and may extend to other diseases. HebeCell is pre-commercial, with therapies currently in development through pharmaceutical partnerships such as Jacobio Pharmaceuticals.

Product overview

HebeCell offers a proprietary 3D-iPSC platform for developing off-the-shelf natural killer (NK) cell therapies. The platform enables scalable production of iPSC-derived NK cells for cancer immunotherapy and potential treatment of other diseases. The company's core technology differentiates itself through a 3D culture system for iPSC expansion and differentiation into NK cells.

Differentiator

Problem solved

Functional benefit

Products and services

• 3D-iPSC Platform

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Jacobio PharmaceuticalscoreStrategic or Co-development Partner · 31 August 2021Jacobio Pharmaceuticals announced a strategic investment in Hebecell to develop iPSC-NK cell therapy, expanding their pipeline into cell-based treatments for cancer and other diseases. The collaboration focuses on off-the-shelf natural killer cell therapies using Hebecell's proprietary 3D-iPSC platform. The deal includes leadership changes and aims to advance clinical and commercial applications of the therapy.

Recent moves4 records

Expansion highlights4 records

Direct peers

• Fate Therapeutics: Clinical-stage pioneer of iPSC-derived NK and T-cell therapies with a proprietary iPSC platform for off-the-shelf cancer cell therapies. Directly comparable to HebeCell in modality (iPSC-derived immune cells) and target indications, with substantially more advanced clinical assets.
• Century Therapeutics: Develops iPSC-derived allogeneic NK and T-cell therapies for cancer using engineered iPSC platforms. Competes in the same iPSC-derived immune cell therapy category as HebeCell and serves overlapping oncology indications.
• Nkarta Therapeutics: Clinical-stage developer of off-the-shelf allogeneic NK cell therapies for cancer, including CAR-NK programs. Closely comparable to HebeCell on modality (allogeneic NK cells) and oncology focus.
• Shoreline Biosciences: Develops iPSC-derived allogeneic NK cell therapies and has established partnerships with major pharma. Operates in the same iPSC-NK modality space as HebeCell with a similar allogeneic, off-the-shelf positioning.
• Cytovia Therapeutics: Clinical-stage biotech developing NK cell therapies including iPSC-derived and gene-edited NK cells for cancer and viral diseases. Directly comparable to HebeCell in modality and indication strategy.

Broad incumbents

• Allogene Therapeutics: Leading allogeneic CAR-T cell therapy developer with multiple clinical programs. Competes in the broader allogeneic cell therapy market HebeCell targets, though focused on T-cells rather than NK cells.
• Caribou Biosciences: Clinical-stage cell and gene therapy company leveraging CRISPR-based allogeneic CAR-NK and CAR-T platforms. Overlaps with HebeCell on allogeneic NK cell therapy for oncology and uses similar iPSC- and genome-editing-enabled approaches.
• Cellectis: Clinical-stage gene-editing company developing allogeneic CAR-T and has expanded into NK-cell-based therapies. A broader incumbent in engineered cell therapy with technology overlap to HebeCell's platform thesis.

Emerging players

• Dragonfly Therapeutics: Developer of NK cell engager therapies and other immune-modulating modalities for cancer and autoimmune disease. Comparable to HebeCell in NK-based therapeutic strategy, though using engager molecules rather than cell therapy.
• Glycostem Therapeutics: Clinical-stage developer of off-the-shelf NK cell therapies (oNKord) derived from cord blood. A smaller allogeneic NK cell competitor with similar off-the-shelf positioning to HebeCell's pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HebeCell